A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS.
Twenty-six patients with poor-risk Kaposi's sarcoma and AIDS were treated with epirubicin 90 mg/m2 intravenously every 3 weeks. One patient achieved complete response and 10 achieved partial response (overall response rate 42.3%). The median time to treatment failure was 22 weeks. The dose-limiting toxicity was neutropenia.